Neisseria meningitidis - Eurosurveillance

More documents

Recommendations

Info

G1407 in Denmark, Romania, Slovakia and Slovenia, accounting for 14–30% of isolates (Figure). G2992 was observed in 14/21 countries and predominated in Ireland and Norway, while G25 predominated in Germany (Figure). <strong>Neisseria</strong> gonorrhoeae multi-antigen sequence typing genogroups and epidemiological characteristics of linked patients The most frequently collected variables were age and sex, known for 1,030 and 1,050 patients, respectively. Sexual orientation was known for only 586 patients (478 males and 108 females) (Table 3). Statistical analysis showed there was no clear association with age category for most genogroups, with the exception of G1407 which was significantly less common in patients aged
Table 4 Consensus antimicrobial susceptibility results for <strong>Neisseria</strong> gonorrhoeae multi-antigen sequence typing genogroups/sequence type represented by 10 or more isolates, EU/EEA countries, 2009–2010 Genogroup or ST Isolates n performs molecular typing of all cases of gonorrhoea in Scotland showed that ST1407 first emerged in 2007 and by 2009 accounted for 15.4% of cases [35]. The current study provides further evidence that the wide dissemination of ST1407 in the EU is likely to be a recent phenomenon. ST1407 and related STs are known to be distributed globally, documented in studies specifically investigating decreased susceptibility and resistance to third generation cephalosporins, in Europe [6,9,13,14,19], the United States [20], Canada [21], Australia [18], Hong Kong [17] and Taiwan [36] and in a survey conducted in Japan [27]. ST1407 has also caused most of the treatment failures with third generation cephalosporins in EU/EEA countries [6-11]. Our study demonstrates that there appear to be no isolates of G1407 that are highly sensitive to cefixime, with 96% of isolates showing MICs ≥0.06mg/L, and presents the first clear evidence that all G1407 isolates circulating currently in the general gonococcal population in the EU/EEA are ciprofloxacin resistant, strongly associated with decreased susceptibility/ resistance to cefixime and show raised MICs for ceftriaxone and azithromycin. This highlights the potential of molecular epidemiological typing as a tool to predict www.eurosurveillance.org Betalactamase Consensus resistance category (Isolates differing from the consensus) Modal MIC mg/L (range) Azithromycin Ciprofloxacin Spectinomycin Gentamicin Cefixime a Ceftriaxonea G1407 248 Negative S (44 b ) R (0) S (0) 8 (4–16) G225 107 Negative S (1 c ) R (0) S (0) 8 (4–16) G2992 84 Negative S (14 d ) S (1) S (0) 8 (2–8) G25 43 Negative S (0) S (1) S (0) 8 (4–8) G387 37 Negative S (0) S (0) S (0) 8 (4–8) G359 20 Negative S (1 c ) S (0) S (0) 8 (4–16) G2 18 Negative S (0) S (0) S (0) 4 (2–8) ST5405 10 Negative S (0) R (0) S (0) 8 (4–8) 0.125 (0.032–0.25) 0.023 (
Page 2:
Editorial team Editorial advisors B
Page 5 and 6:
genome sequencing technologies, we
Page 7 and 8:
References 1. Struelens MJ, De Ghel
Page 9 and 10:
e procedures in place to check and
Page 11 and 12:
microorganisms [23]. After PCR, amp
Page 13 and 14:
of the based upon repeat patterns (
Page 15 and 16:
two days. Due to a very high accura
Page 17 and 18:
eported a clinically meaningful app
Page 19 and 20:
18. Chang HL, Tang CH, Hsu YM, Wan
Page 21 and 22:
from: http://www.eurosurveillance.o
Page 23 and 24:
Table 1 Online molecular typing dat
Page 25 and 26:
Table 2 Currently available softwar
Page 27 and 28: Current concepts and technologies f
Page 29 and 30: References 1. Hesper B, Hogeweg P.
Page 31 and 32: Review articles Automated extractio
Page 33 and 34: diverse organisms, such as the meni
Page 35 and 36: Figure 2 Extracting antigen and ant
Page 37 and 38: Figure 3 Relationships of 139 Neiss
Page 39 and 40: 25. Wirth T, Hildebrand F, Allix-B
Page 41 and 42: Euroroundups Use of multilocus vari
Page 43 and 44: searches were also repeated using G
Page 45 and 46: Table 2 MLVA analysis of Salmonella
Page 47 and 48: anthracis [15], worldwideadopted, b
Page 49 and 50: As MLVA assays rely on the informat
Page 51 and 52: Research articles Current applicati
Page 53 and 54: Table 2 Techniques, time and costs
Page 58 and 59: common C. difficile variants causin
Page 60 and 61: References 1. Bartlett JG. Antibiot
Page 62 and 63: Research articles Within-patient em
Page 64 and 65: Figure 1 Phylogenetic reconstructio
Page 66: Table 2 Prevalence of haemagglutini
Page 69 and 70: Of the 13 patients with 222G mutant
Page 71 and 72: of virulence, such a mechanism may
Page 73 and 74: Research articles Molecular epidemi
Page 75 and 76: Table 1 Most frequently observed Ne
Page 80 and 81: Treatment failure in patients infec
Page 82 and 83: 31. Buono S, Wu A, Hess DC, Carlson
Page 84 and 85: Irish Mycobacteria Reference Labora
Page 86: Table 2 Clusters of Mycobacterium t
Page 89 and 90: multifunctional database for online
Page 93 and 94: of a laboratory network, which also
Page 95 and 96: References 1. Bean NH, Martin SM. I
Page 97 and 98: Mebendazole was first administered
Page 99 and 100: Figure 4 Neighbour-joining tree bas
Page 101 and 102: Acknowledgments We gratefully thank
Page 103: epidemiologically relevant variants
Page 106 and 107: as possible to be performed with si
Page 108 and 109: Perspectives The need for ethical r
Page 110 and 111: ‘voluntary’, and ‘decisionall
Page 112 and 113: Perspectives Molecular-based survei
Page 114 and 115: Figure 2 Human cases of campylobact
Page 116 and 117: an integrated way [36,37]. This may
Page 118 and 119: 21. Jolley KA, Bliss CM, Bennett JS
Page 120 and 121: News ECDC starts pilot phase for co
Page 122 and 123: Poland Meldunki o zachorowaniach na
Page 124 and 125: 122 www.eurosurveillance.org
show all

Neisseria meningitidis - Eurosurveillance

Create successful ePaper yourself

Delete template?

Save as template?